Inhibition of ovarian steroidogenesis by cyclic GMP in a fly.
Previous investigations in the female blowfly Phormia regina have shown that 3-isobutyl-1-methylxanthine (IBMX), a broad spectrum inhibitor of phosphodiesterases (PDEs), fails to mimic the steroidogenic effects of cAMP on ovaries, although it efficiently increases the concentrations of this second messenger. In this study, experiments carried out to clear up this contradiction demonstrated that IBMX, besides its effect on cAMP, also increased cGMP concentrations in blowfly ovary and that these two cyclic nucleotides controlled ovarian steroidogenesis antagonistically. In particular, a selective inhibitor of cGMP-specific PDEs, unlike IBMX, had a very strong negative effect on ovarian steroidogenesis. Moreover, a cGMP analog was able to inhibit steroid biosynthesis in previtellogenic and vitellogenic ovaries, thus affecting basal and acute steroidogenesis respectively. Our observations also demonstrated that cGMP was always present in blowfly ovary, reaching its maximal levels at the end of vitellogenesis, in close correlation with the physiological decrease in ovarian steroidogenesis. Experiments using an inhibitor of protein kinase G clearly indicated that the effects of cGMP were mediated by this enzyme. On the contrary, these effects did not seem to involve cGMP-regulated PDEs or ion channels. Our results also indicated that ovarian cGMP concentrations were not controlled by brain factors, suggesting a probable involvement of paracrine/autocrine factors. Nitric oxide (NO) appeared to be a good candidate for such a control, because an NO donor was able to stimulate ovarian cGMP concentrations and to drastically decrease ovarian ecdysteroid biosynthesis in blowflies. These data thus demonstrate, for the first time in invertebrates, a potent role of cGMP in the negative control of ovarian steroidogenesis and suggest a possible co-regulation with NO.
Manière
G
G
Université Bordeaux I, Laboratoire de Neuroendocrinologie des Insectes, Avenue des Facultés, F-33405 Talence Cedex, France.
Vanhems
E
E
Gautron
F
F
Delbecque
J-P
JP
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000378:metabolism; D015220:Calcium Channels / Q000378:metabolism; D002227:Carbazoles; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism / Q000494:pharmacology; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology; D017869:Cyclic GMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors; D004175:Diptera / Q000378:metabolism*; D026461:Ecdysteroids / Q000096:biosynthesis*; D005260:Female; D007211:Indoles; D009924:Organ Culture Techniques; D010053:Ovary / Q000187:drug effects / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D015398:Signal Transduction / Q000502:physiology*; D013268:Stimulation, Chemical
C474800:4-((3',4'-(methylenedioxy)benzyl)amino-6-methoxy-quinazoline); D000470:Alkaloids; C474799:CPT-cGMP; D015220:Calcium Channels; D002227:Carbazoles; D026461:Ecdysteroids; D007211:Indoles; D010726:Phosphodiesterase Inhibitors; D011799:Quinazolines; C073601:KT 5823; D005576:Colforsin; C010192:9-(2-hydroxy-3-nonyl)adenine; D000242:Cyclic AMP; D017869:Cyclic GMP-Dependent Protein Kinases; D006152:Cyclic GMP; D000225:Adenine; D015056:1-Methyl-3-isobutylxanthine